

1. NAME OF THE MEDICINAL PRODUCT

Binozyt® 200mg/5ml Powder for Oral Suspension

2. QUALITATIVE AND QUANTITATIVE COMPOSITION

5 mL made-up Binozyt® 200 mg/5ml Powder for Oral Suspension contains 204.8 mg azithromycin monohydrate equivalent to 200 mg azithromycin.

For a full list of excipients, see section 6.1.

3. PHARMACEUTICAL FORM

Powder for oral suspension.

White to off white coloured powder; after reconstitution with water resulting in a white to off white coloured homogenous suspension.

4. CLINICAL PARTICULARS

4.1 Therapeutic indications

Binozyt can be applied in situations where micro-organisms sensitive to azithromycin have caused:

- upper respiratory tract infections: sinusitis, pharyngitis, tonsillitis
- acute otitis media
- lower respiratory tract infections: acute bronchitis and mild to moderately severe community acquired pneumonia
- skin and soft tissue infections
- uncomplicated *Chlamydia trachomatis* urethritis and cervicitis

Considerations should be given to official guidance on the appropriate use of antibacterial agents.

4.2 Posology and method of administration

Adults

In uncomplicated *Chlamydia trachomatis* urethritis and cervicitis, the dose is 1,000 mg as a single oral dose.

For all other indications, the dose is 1,500 mg, to be administered as 500 mg per day for three consecutive days. As an alternative, the same total dose (1,500 mg) can also be administered over a period of 5 days with 500 mg on the first day and 250 mg on the second to the fifth day.

Older people

The same dose as in adult patients is used in older people. Since older patients can be patients with ongoing proarrhythmic conditions a particular caution is recommended due to the risk of developing cardiac arrhythmia and torsades de pointes (see section 4.4).

Paediatric population

Azithromycin tablets should only be administered to children weighing more than 45 kg when normal adult dose should be used. For children under 45 kg other pharmaceutical forms of azithromycin, e.g., suspensions, may be used.

The total dose in children aged 1 year and older is 30 mg/kg administered once a day or 10 mg/kg over three days, or over a period of five days starting with a single dose of 10 mg/kg on the first day, followed by doses of 5 mg/kg per day for the following 4 days, according to the tables shown below.

Weight (kg)	3-day therapy	5-day therapy	
	Day 1-3 10 mg/kg/day	Day 1 10 mg/kg/day	Day 2-5 5 mg/kg/day
< 15	10 mg/kg once daily	10 mg/kg once daily	5 mg/kg once daily
15-25	200 mg (5 mL) once daily	200 mg (5 mL) once daily	100 mg (2.5 mL) once daily
26-35	300 mg (7.5 mL) once daily	300 mg (7.5 mL) once daily	150 mg (3.75 mL) once daily
36-45	400 mg (10 mL) once daily	400 mg (10 mL) once daily	200 mg (5 mL) once daily
>45	Dose as per adults	Dose as per adults	Dose as per adults

The dose for the treatment of pharyngitis caused by *Streptococcus pyogenes* is an exception: in the treatment of pharyngitis caused by *Streptococcus pyogenes* Azithromycin has proved to be effective when it is administered to children as a single dose of 10 mg/kg or 20 mg/kg for 3 days with a maximum daily dose of 500 mg. At these two doses a comparable clinical effect was observed, even if the eradication of the bacteria was more significant at a daily dosage of 20 mg/kg.

Penicillin is however the drug of first choice in the treatment of pharyngitis caused by *Streptococcus pyogenes* and the prevention of subsequent rheumatic fever.

In patients with renal impairment

No dose adjustment is necessary in patients with mild to moderate renal impairment (GFR 10 - 80 mL/min) (see sections 4.4 and 5.2).

In patients with hepatic impairment

A dose adjustment is not necessary for patients with mild to moderately impaired liver function (see section 4.4 and 5.2).

Method of administration

Before use, the powder should be reconstituted with water, see preparation of the suspension. After reconstitution, the drug can be administered using a PE/PP syringe for oral use.

After taking the suspension, a bitter after-taste can be avoided by drinking fruit juice directly after swallowing. Azithromycin powder for oral suspension should be given in a single daily dose. The suspension can be taken together with food.

Preparation of the suspension:

Shake the dry powder loose. Add the amount of water described below to the powder.

Azithromycin 200 mg/5 mL:

For 15 mL (600 mg) bottle: add 8 mL water.

Shake well until a homogenous suspension is achieved. For administration the syringe adapter should be placed in the neck of the bottle and the stopper should be opened.

4.3 Contraindications

Hypersensitivity to the active substance, erythromycin, any macrolide or ketolide antibiotic, or to any of the excipients.

4.4 Special warnings and special precautions for use

Hypersensitivity

As with erythromycin and other macrolides, rare serious allergic reactions, including angioneurotic oedema and anaphylaxis (rarely fatal), and dermatologic reactions including acute generalised exanthematous pustulosis (AGEP), Stevens-Johnson Syndrome (SJS), toxic epidermal necrolysis (TEN) (rarely fatal), and drug reaction with eosinophilia and systemic symptoms (DRESS) have been reported. Some of these reactions with azithromycin have resulted in recurrent symptoms and required a longer period of observation and treatment.

If an allergic reaction occurs, the medicinal product should be discontinued and appropriate therapy should be instituted. Physicians should be aware that reappearance of the allergic symptoms may occur when symptomatic therapy is discontinued.

NPRA Directive

In the event of severe acute hypersensitivity reactions, such as anaphylaxis, severe cutaneous adverse reactions (SCARs) [e.g., Stevens-Johnson Syndrome (SJS), toxic epidermal necrolysis (TEN), drug reaction with eosinophilia and systemic symptoms (DRESS) & acute generalised exanthematous pustulosis (AGEP)], Binozyt should be discontinued immediately and appropriate treatment should be urgently initiated.

Hepatotoxicity

Since the liver is the principal route of elimination for azithromycin, the use of azithromycin should be undertaken with caution in patients with significant hepatic disease. Cases of fulminant hepatitis potentially leading to life-threatening liver failure have been reported with azithromycin (see section 4.8). Some patients may have had pre-existing hepatic disease or may have been taking other hepatotoxic medicinal products.

In case of signs and symptoms of liver dysfunction, such as rapid developing asthenia associated with jaundice, dark urine, bleeding tendency or hepatic encephalopathy, liver function tests/investigations should be performed immediately. Azithromycin administration should be stopped if liver dysfunction has emerged.

Abnormal liver function, hepatitis, cholestatic jaundice, hepatic necrosis, and hepatic failure have been reported, some of which have resulted in death. Discontinue azithromycin immediately if signs and symptoms of hepatitis occur.

Infantile hypertrophic pyloric stenosis (IHPS)

Following the use of azithromycin in infants (treatment up to 42 days of life), infantile hypertrophic pyloric stenosis (IHPS) has been reported. Parents and caregivers should be informed to contact their physician if vomiting and/or irritability with feeding occurs.

Pseudomembranous colitis

Pseudomembranous colitis has been reported with the use of macrolide antibiotics. This diagnosis should therefore be considered in patients who get diarrhoea after starting treatment with azithromycin.

Ergot derivatives

In patients receiving ergot derivatives, ergotism has been precipitated by co-administration of some macrolide antibiotics. There are no data concerning the possibility of an interaction between ergot and azithromycin. However, because of the theoretical possibility of ergotism, azithromycin and ergot derivatives should not be co-administered.

Superinfection

As with any antibiotic preparation, observation for signs of superinfection with non-susceptible organisms, including fungi is recommended.

Cross-resistance

Because of existing cross-resistance with erythromycin-resistant gram-positive strains and most strains of methicillin resistant staphylococci, use of azithromycin is not recommended. Local epidemiology and susceptibility patterns should be taken into consideration.

Serious infections

Azithromycin is not intended to treat suitable severe infections, where fast high blood concentrations of antibiotic have to be achieved.

Clostridium difficile associated diarrhoea

Clostridium difficile associated diarrhea (CDAD) has been reported with use of nearly all antibacterial agents, including azithromycin, and may range in severity from mild diarrhea to fatal colitis. Treatment with antibacterial agents alters the normal flora of the colon leading to overgrowth of *C. difficile*.

C. difficile produces toxins A and B which contribute to the development of CDAD.

Hypertoxin producing strains of *C. difficile* cause increased morbidity and mortality, as these infections can be refractory to antimicrobial therapy and may require colectomy. CDAD must be considered in all patients who present with diarrhea following antibiotic use. Careful medical history is necessary since CDAD has been reported to occur over two months after the administration of antibacterial agents.

Renal impairment

In patients with severe renal impairment (GFR <10 ml/min), a 33% increase in systemic exposure to azithromycin was observed (see section 5.2).

Cardiovascular events

Prolonged cardiac repolarization and QT interval, imparting a risk of developing cardiac arrhythmia and torsades de pointes, have been seen in treatment with macrolides including azithromycin (see section 4.8). Therefore as the following situations may lead to an increased risk for ventricular arrhythmias (including torsade de pointes) which can lead to cardiac arrest, azithromycin should be used with caution in patients with ongoing proarrhythmic conditions (especially women and elderly patients). Prescribers should consider the risk of QT prolongation, which can be fatal, when weighing the risks and benefits of azithromycin for at-risk groups including:

- Patients with congenital or documented QT prolongation
- Patients currently receiving treatment with other active substances known to prolong QT interval, such as antiarrhythmics of Class IA (quinidine and procainamide) and class III (dofetilide, amiodarone and sotalol), cisapride and terfenadine; antipsychotic agents such as pimozide; antidepressants such as citalopram; and fluoroquinolones such as moxifloxacin and levofloxacin
- Patients with electrolyte disturbance, particularly in cases of hypokalemia and hypomagnesemia
- Patients with clinically relevant bradycardia, cardiac arrhythmia or cardiac insufficiency
- Elderly patients: elderly patients may be more susceptible to drug-associated effects on the QT interval

Epidemiological studies investigating the risk of adverse cardiovascular outcomes with macrolides have shown variable results. Some observational studies have identified a rare short-term risk of arrhythmia, myocardial infarction and cardiovascular mortality associated with macrolides including azithromycin. Consideration of these findings should be balanced with treatment benefits when prescribing azithromycin.

Myasthenia gravis

Exacerbations of the symptoms of myasthenia gravis and new onset of myasthenia syndrome have been reported in patients receiving azithromycin therapy (see section 4.8).

Paediatric population

Safety and efficacy for the prevention or treatment of *Mycobacterium Avium* complex in children have not been established.

Long-term use

There is no experience on safety and effectiveness of long-term use of azithromycin in indications mentioned before. At fast recurrent infections treatment with other antibiotics should be considered.

Neurological and psychiatric disorders

Azithromycin should be used with caution in patients with neurological and psychiatric disorder.

Aspartame: Unsuitable for phenylketonurics.

4.5 Interactions with other medicinal products and other forms of interaction

Antacids

Simultaneous administration of antacid with azithromycin, no effect on overall bioavailability was seen although peak serum concentrations were reduced by approximately 24%. In patients receiving both azithromycin and antacids, the medicinal products should not be taken simultaneously.

Cetirizine

Co-administration of a 5-day regimen of azithromycin with cetirizine 20 mg at steady-state resulted in no pharmacokinetic interaction and no significant changes in the QT interval.

Didanosine (Dideoxyinosine)

Co-administration of 1,200 mg/day azithromycin with 400 mg/day didanosine did not appear to affect the steady-state pharmacokinetics of didanosine.

Digoxin and colchicine (P-gp substrates)

Concomitant administration of macrolide antibiotics, including azithromycin, with P-glycoprotein substrates such as digoxin and colchicine, has been reported to result in increased serum levels of the P-glycoprotein substrate. Therefore, if azithromycin and P-gp substrates such as digoxin are administered concomitantly, the possibility of elevated serum concentrations of the substrate should be considered.

Ergot derivatives

Due to the theoretical possibility of ergotism, the concurrent use of azithromycin with ergot derivatives is not recommended (see section 4.4).

Zidovudine

Single 1,000 mg doses and multiple 1,200 mg or 600 mg doses of azithromycin had little effect on the plasma pharmacokinetics or urinary excretion of zidovudine or its glucuronide metabolite. However, administration of azithromycin increased the concentrations of phosphorylated zidovudine, the clinically

active metabolite, in peripheral blood mononuclear cells. The clinical significance of this finding is unclear, but it may be of benefit to patients.

Azithromycin does not interact significantly with the hepatic cytochrome P450 system. It is not believed to undergo the pharmacokinetic drug interactions as seen with erythromycin and other macrolides. Hepatic cytochrome P450 induction or inactivation via cytochrome-metabolite complex does not occur with azithromycin.

Pharmacokinetic studies have been conducted between azithromycin and the following medicinal products known to undergo significant cytochrome P450 mediated metabolism.

Atorvastatin

Co-administration of atorvastatin (10 mg daily) and azithromycin (500 mg daily) did not alter the plasma concentrations of atorvastatin (based on a HMG CoA-reductase inhibition assay). However, post-marketing cases of rhabdomyolysis in patients receiving azithromycin with statins have been reported.

Carbamazepine

No significant effect was observed on the plasma levels of carbamazepine or its active metabolite in patients receiving concomitant azithromycin.

Cimetidine

The effects of a single dose of cimetidine, given 2 hours before azithromycin, on the pharmacokinetics of azithromycin, no alteration of azithromycin pharmacokinetics was seen.

Coumarin-type oral anticoagulants

Azithromycin did not alter the anticoagulant effect of a single 15 mg dose of warfarin administered. There have been reports received in the post-marketing period of potentiated anticoagulation subsequent to co-administration of azithromycin and coumarin-type oral anticoagulants. Although a causal relationship has not been established, consideration should be given to the frequency of monitoring prothrombin time when azithromycin is used in patients receiving coumarin-type oral anticoagulants.

Ciclosporin

Administration of a 500 mg/day oral dose of azithromycin for 3 days and were then administered a single 10 mg/kg oral dose of ciclosporin, the resulting ciclosporin C_{max} and AUC_{0-5} were found to be significantly elevated. Consequently, caution should be exercised before considering concurrent administration of these medicinal products. If co-administration of these medicinal products is necessary, ciclosporin levels should be monitored and the dose adjusted accordingly.

Efavirenz

Co-administration of a 600 mg single dose of azithromycin and 400 mg efavirenz daily for 7 days did not result in any clinically significant pharmacokinetic interactions.

Fluconazole

Co-administration of a single dose of 1,200 mg azithromycin did not alter the pharmacokinetics of a single dose of 800 mg fluconazole. Total exposure and half-life of azithromycin were unchanged by the co-administration of fluconazole, however, a clinically insignificant decrease in C_{max} (18%) of azithromycin was observed.

Indinavir

Co-administration of a single dose of 1,200 mg azithromycin had no statistically significant effect on the pharmacokinetics of indinavir administered as 800 mg three times daily for 5 days.

Methylprednisolone

Azithromycin had no significant effect on the pharmacokinetics of methylprednisolone.

Midazolam

Co-administration of azithromycin 500 mg/day for 3 days did not cause clinically significant changes in the pharmacokinetics and pharmacodynamics of a single 15 mg dose of midazolam.

Nelfinavir

Co-administration of azithromycin (1,200 mg) and nelfinavir at steady state (750 mg three times daily) resulted in increased azithromycin concentrations. No clinically significant adverse effects were observed and no dose adjustment is required.

Rifabutin

Co-administration of azithromycin and rifabutin did not affect the serum concentrations of either medicinal product.

Neutropenia was observed in subjects receiving concomitant treatment of azithromycin and rifabutin. Although neutropenia has been associated with the use of rifabutin, a causal relationship to combination with azithromycin has not been established (see section 4.8).

Sildenafil

There was no evidence of an effect of azithromycin (500 mg daily for 3 days) on the AUC and C_{max} of sildenafil or its major circulating metabolite.

Terfenadine

Pharmacokinetic studies have reported no evidence of an interaction between azithromycin and terfenadine. There have been rare cases reported where the possibility of such an interaction could not be entirely excluded; however there was no specific evidence that such an interaction had occurred.

Theophylline

There is no evidence of a clinically significant pharmacokinetic interaction when azithromycin and theophylline are co-administered to healthy volunteers.

Triazolam

Co-administration of azithromycin 500 mg on Day 1 and 250 mg on Day 2 with 0.125 mg triazolam on Day 2 had no significant effect on any of the pharmacokinetic variables for triazolam compared to triazolam and placebo.

Trimethoprim/sulfamethoxazole

Co-administration of trimethoprim/sulfamethoxazole (160 mg/800 mg) for 7 days with azithromycin 1,200 mg on Day 7 had no significant effect on peak concentrations, total exposure or urinary excretion of either trimethoprim or sulfamethoxazole. Azithromycin serum concentrations were similar to those seen in other studies.

Other antibiotics

On a possible co-resistance between macrolide antibiotics and azithromycin (e.g., erythromycin) as well as lincomycin and clindamycin is to look at. Concomitant use of several medicinal products from the same group of substances is not recommended.

Medicinal products known to prolong the QT interval

Azithromycin should not be co-administered with other medicinal products, known to prolong the QT interval (see section 4.4).

4.6 Pregnancy and Lactation

Pregnancy

There are no adequate data from the use of azithromycin in pregnant women. In reproduction toxicity studies in animals azithromycin was shown to pass the placenta, but no teratogenic effects were observed. The safety of azithromycin has not been confirmed with regard to the use of the active substance during pregnancy. Therefore azithromycin should only be used during pregnancy if the benefit outweighs the risk.

Breastfeeding

Azithromycin has been reported to be secreted into human breast milk, but there are no adequate and well-controlled clinical studies in breastfeeding women that have characterized the pharmacokinetics of azithromycin excretion into human breast milk.

Fertility

In fertility studies conducted in rat, reduced pregnancy rates were noted following administration of azithromycin. The relevance of this finding to humans is unknown.

4.7 Effects on ability to drive and use machines

There is no evidence to suggest that azithromycin may have an effect on a patient's ability to drive or operate machinery.

However, certain adverse reactions, visual impairment and vision blurred may have an effect on a patient's ability to drive or operate machinery (section 4.8).

4.8 Undesirable effects

Below the adverse reactions identified through clinical trial experience and post-marketing surveillance by system organ class and frequency are listed.

The frequency grouping is defined using the following convention:

Very common	($\geq 1/10$);
Common	($\geq 1/100$ to $<1/10$);
Uncommon	($\geq 1/1,000$ to $<1/100$);
Rare	($\geq 1/10,000$ to $<1/1,000$);
Very Rare	($< 1/10,000$); and
Not known	(cannot be estimated from the available data).

Within each frequency grouping, undesirable effects are presented in order of decreasing seriousness.

Approximately 13% of patients in clinical trials reported adverse events, wherein gastrointestinal disorders were the most common.

Adverse reactions possibly or probably related to azithromycin based on clinical trial experience and post-marketing surveillance:

Infections and infestations

Uncommon:	Candidiasis, vaginal infection, pneumonia, fungal infections, bacterial infection, pharyngitis, gastroenteritis, respiratory disorder, rhinitis, oral candidiasis
Not known:	Pseudomembranous colitis (see section 4.4)

Blood and lymphatic system disorders

Uncommon:	Leukopenia, neutropenia, eosinophilia
Not known:	Thrombocytopenia, haemolytic anaemia

Immune system disorders

Uncommon:	Angioedema, hypersensitivity
Not known:	Severe (partly fatal) anaphylactic reaction e.g., anaphylactic shock (see section 4.4)

Metabolism and nutrition disorders

Uncommon:	Anorexia
-----------	----------

Psychiatric disorders

Uncommon:	Nervousness, insomnia
Rare:	Agitation
Not known:	Aggression, anxiety, delirium, hallucination

Nervous system disorders

Common:	Headache
Uncommon:	Dizziness, somnolence, dysgeusia, paraesthesia
Not known:	Syncope, convulsion, hypoaesthesia, psychomotor hyperactivity, anosmia, ageusia, parosmia, myasthenia gravis (see section 4.4)

Eye disorders

Uncommon:	Visual impairment
Not known:	Blurred vision

Ear and labyrinth disorders

Uncommon:	Ear disorder, vertigo
-----------	-----------------------

Not known: Hearing impairment including deafness and/or tinnitus

Cardiac disorders

Uncommon: Palpitations

Not known: Torsades de pointes (see section 4.4), arrhythmia (see section 4.4) including ventricular tachycardia, electrocardiogram QT prolonged (see section 4.4)

Vascular disorders

Uncommon: Hot flush

Not known: Hypotension

Respiratory, thoracic and mediastinal disorders

Uncommon: Dyspnoea, epistaxis

Gastrointestinal disorders

Very common: Diarrhea

Common: Vomiting, abdominal pain, nausea

Uncommon: Constipation, flatulence, dyspepsia, gastritis, dysphagia, abdominal distension, dry mouth, eructation, mouth ulceration, salivary hypersecretion

Not known: Pancreatitis, tongue discoloration

Hepatobiliary disorders

Rare: Hepatic function abnormal, jaundice cholestatic

Not known: Hepatic failure (which has rarely resulted in death) (see section 4.4), hepatitis fulminant, hepatic necrosis

Skin and subcutaneous disorders

Uncommon: Rash, pruritus, urticaria, dermatitis, dry skin, hyperhidrosis

Rare: Photosensitivity reaction, acute generalised exanthematous pustulosis (AGEP)

Very rare: DRESS (drug reaction with eosinophilia and systemic symptoms)*

Not known: Stevens-Johnson syndrome, toxic epidermal necrolysis, erythema multiforme

*Frequency estimated with the "rule of three"

NPRA Directive

Not known: Severe cutaneous adverse reactions (SCARs) including Stevens-Johnson Syndrome (SJS), toxic epidermal necrolysis (TEN), drug reaction with eosinophilia and systemic symptoms (DRESS) & acute generalised exanthematous pustulosis (AGEP)

Musculoskeletal and connective tissue disorders

Uncommon: Osteoarthritis, myalgia, back pain, neck pain

Not known: Arthralgia

Renal and urinary disorders

Uncommon: Dysuria, renal pain

Not known: Renal failure acute, nephritis interstitial

Reproductive system and breast disorders

Uncommon: Metrorrhagia, testicular disorder

General disorders and administration site conditions

Uncommon: Oedema, asthenia, malaise, fatigue, face edema, chest pain, pyrexia, pain, peripheral edema

Investigations

Common: Lymphocyte count decreased, eosinophil count increased, blood bicarbonate decreased, basophils increased, monocytes increased, neutrophils increased

Uncommon: Aspartate aminotransferase increased, alanine aminotransferase increased, blood bilirubin increased, blood urea increased, blood creatinine increased, blood potassium abnormal, blood alkaline phosphatase increased, chloride increased, glucose increased, platelets increased, hematocrit decreased, bicarbonate increased, abnormal sodium

Injury and poisoning

Uncommon: Post procedural complication

Post-marketing experience

Cardiac Disorders: Palpitations and arrhythmias including ventricular tachycardia have been reported. There have been rare reports of QT prolongation and torsades de pointes (see section 4.4) (NPRA directive).

Gastrointestinal Disorders: infantile hypertrophic pyloric stenosis (NPRA directive).

Adverse reactions possibly or probably related to *Mycobacterium avium* complex prophylaxis and treatment based on clinical trial experience and post-marketing surveillance. These adverse reactions differ from those reported with immediate-release or the prolonged-release formulations, either in kind or in frequency:

Metabolism and nutrition disorders

Common: Anorexia

Nervous system disorders

Common: Dizziness, headache, paraesthesia, dysgeusia

Uncommon: Hypoaesthesia

Eye disorders

Common: Visual impairment

Ear and labyrinth disorders

Common: Deafness

Uncommon: Hearing impaired, tinnitus

Cardiac disorders

Uncommon: Palpitations

Gastrointestinal disorders

Very common: Diarrhea, abdominal pain, nausea, flatulence, abdominal discomfort, loose stools

Hepatobiliary disorders

Uncommon: Hepatitis

Skin and subcutaneous tissue disorders

Common: Rash, pruritus

Uncommon: Stevens-Johnson syndrome, photosensitivity reaction

Musculoskeletal and connective tissue disorders

Common: Arthralgia

General disorders and administration site conditions

Common: Fatigue

Uncommon: Asthenia, malaise

4.9 Overdose

Adverse events experienced in higher than recommended doses were similar to those seen at normal doses. The typical symptoms of an overdose with macrolide antibiotics include reversible loss of hearing, severe nausea, vomiting and diarrhoea.

In the event of overdose, the administration of medicinal charcoal and general symptomatic treatment and supportive measures are indicated as required.

5. PHARMACOLOGICAL PROPERTIES

5.1 Pharmacodynamic properties

Pharmacotherapeutic group: Antibacterials for systemic use, macrolides, lincosamides and streptogramins, macrolides

ATC Code: J01FA10

Mode of action

Azithromycin is an azalide, a sub-class of the macrolide antibiotics. By binding to the 50S-ribosomal sub-unit, azithromycin avoids the translocation of peptide chains from one side of the ribosome to the other. Azithromycin acts bacteriostatic.

PK/PD relationship

The efficacy of azithromycin is best described by the relationship AUC/MIC, where AUC describes the area under the curve and MIC represents the mean inhibitory concentration of the microbe concerned.

Mechanism of resistance

Resistance to azithromycin may be natural or acquired. There are 3 main mechanisms of resistance affecting azithromycin:

- Efflux: resistance may be due to an increase in the number of efflux pumps on the cell membrane. In particular, 14- and 15-link macrolides are affected. (M-phenotype)
- Alterations of the cell structure: methylation of the 23s rRNS may reduce the affinity of the ribosomal binding sites, which can result in microbial resistance to macrolides, lincosamides and group B streptogramins (SB) (MLSB-phenotype).
- Enzymatic deactivation of macrolides is only of limited clinical significance.

In the presence of the M-phenotype, complete cross-resistance exists between azithromycin and clarithromycin, erythromycin and roxithromycin. With the MLSB-phenotype, additional cross-resistance exists with clindamycin and streptogramin B. A partial cross-resistance exists with spiramycin.

Breakpoints

Testing of azithromycin is done by using the usual dilution series. The following minimum inhibitory concentrations for susceptible and resistant germs were determined:

EUCAST (European Committee on Antimicrobial Susceptibility Testing)

Pathogens	S≤ (mg/l)	R> (mg/l)
<i>Staphylococcus</i> spp.	1 ^a	2 ^a
<i>Streptococcus</i> spp. (groups A, B, C, G)	0.25 ^a	0.5 ^a
<i>Streptococcus pneumoniae</i>	0.25 ^a	0.5 ^a
<i>Haemophilus influenzae</i>	Note ^b	Note ^b
<i>Moraxella catarrhalis</i>	0.25 ^a	0.5 ^a
<i>Neisseria gonorrhoeae</i>	0.25	0.5
<i>Campylobacter jejuni</i> and <i>coli</i>	Note ^c	Note ^c
<i>Kingella kingae</i>	0.25 ^d	0.25 ^d
Viridans group streptococci	IE	IE
PK-PD (non-species related) breakpoints	IE	IE

^a Erythromycin can be used to determine susceptibility to azithromycin, clarithromycin and roxithromycin.

^b Clinical evidence for the efficacy of macrolides in *H. influenzae* respiratory infections is conflicting due to high spontaneous cure rates. Should there be a need to test any macrolide against this species, the epidemiological cut-offs (ECOFFs) should be used to detect strains with acquired resistance. The ECOFFs for each agent are: azithromycin 4 mg/l, clarithromycin 32 mg/l, erythromycin 16 mg/l and telithromycin 8 mg/l. There are insufficient data available to establish an ECOFF for roxithromycin.

^c Erythromycin can be used to determine susceptibility to azithromycin and clarithromycin.

^d Susceptibility can be inferred from erythromycin susceptibility.

IE Indicates that there is insufficient evidence that the organism or group is a good target for therapy with the agent. An MIC with a comment but without an accompanying S, I or R categorisation may be reported

Susceptibility

The prevalence of acquired resistance may vary geographically and with time for selected species and local information on resistance is desirable, particularly when treating severe infections. As necessary, expert advice should be sought when the local prevalence of resistance is such that the utility of the agent in at least some types of infections is questionable.

Microbiological diagnosis with detection of the pathogen and its susceptibility to azithromycin should be attempted, particularly in the case of serious infections or treatment failures.

Table of susceptibility

Commonly susceptible species
Aerobic Gram-positive microorganisms
<i>Mycobacterium avium</i> ⁰
<i>Streptococcus pyogenes</i>
Aerobic Gram-negative microorganisms
<i>Haemophilus influenza</i> ^{\$}
<i>Legionella pneumophila</i> ⁰
<i>Moraxella catarrhalis</i>
<i>Neisseria gonorrhoeae</i>
Other microorganisms
<i>Chlamydia trachomatis</i> ⁰
<i>Chlamydophila pneumoniae</i> ⁰
<i>Mycoplasma pneumonia</i> ⁰
Species for which acquired resistance may be a problem
Aerobic Gram-positive microorganisms
<i>Staphylococcus aureus</i> (methicillin-sensitive)
<i>Staphylococcus aureus</i> (methicillin-resistant) ⁺
<i>Staphylococcus epidermidis</i>
<i>Staphylococcus haemolyticus</i>
<i>Staphylococcus hominis</i>
<i>Streptococcus agalactiae</i>
<i>Streptococcus pneumoniae</i> ^Ω
Inherently resistant organisms
Aerobic Gram-negative microorganisms
<i>Escherichia coli</i>
<i>Klebsiella</i> spp.
<i>Pseudomonas aeruginosa</i>

⁰ There was no current data available at the time of publishing this table. Susceptibility is assumed in the primary literature, standard works and therapeutic recommendations.

^{\$} The natural sensitivity of most isolates lies in the intermediate range

⁺ Rate of resistance is over 50% in at least one region.

^Ω In isolates of invasive disease the rate of resistance is <10%.

5.2 Pharmacokinetic properties

Absorption

After oral administration, peak plasma levels are reached after 2 to 3 hours; plasma terminal elimination half-life closely reflects the tissue depletion half-life of 2 to 4 days. After a 5 day treatment slightly higher AUC values were seen in the elderly patients (>65 years of age) compared to the younger patients (<40 years of age). However, these differences are not regarded as clinically relevant; therefore a dose adjustment is not recommended.

Non-linearity

Study data suggest non-linear pharmacokinetics of azithromycin in the therapeutic range.

Distribution

It has been demonstrated that the concentrations of azithromycin measured in tissues are noticeably higher

(as much as 50 times) than those measured in plasma, which indicates that the agent strongly binds to tissues. Concentrations in target tissues such as lung, tonsil, and prostate exceed the MIC₉₀ for likely pathogens after a single dose of 500 mg.

Binding to serum proteins varies according to plasma concentration and ranges from 12% at 0.5 µg/ml up to 52% at 0.05 µg azithromycin/ml serum. The mean volume of distribution at steady state (V_{ss}) has been calculated to be 31.1 l/kg.

Elimination

About 12% of an intravenously administered dose is excreted unchanged within 3 days; the majority is excreted in the first 24 hours. Particularly high concentrations of unchanged azithromycin have been found in human bile. Also in bile, 10 metabolites were detected, which were formed through N- and O-demethylation, hydroxylation of desosamine and aglycone rings and cleavage of cladinose conjugate. Corresponding studies indicate that the metabolites of azithromycin are not microbiologically active.

Pharmacokinetics in special populations

Renal insufficiency

Following a single oral dose of azithromycin 1 g, pharmacokinetics were unchanged in subjects with a glomerular filtration rate <10 ml/min, there were statistically significant differences compared with subjects with normal renal function (GFR >80 ml/min) in AUC₀₋₁₂₀ (8.8 µg x h/ml vs. 11.7 µg x h/ml), C_{max} (1.0 µg/ml vs. 1.6 µg/ml) and CL_r (2.3 ml/min/kg vs. 0.2 ml/min/kg).

Hepatic insufficiency

In patients with mild to moderate hepatic impairment, there is no evidence of a marked change in serum pharmacokinetics of azithromycin compared to normal hepatic function. In these patients, urinary recovery of azithromycin appears to increase perhaps to compensate for reduced hepatic clearance.

6. PHARMACEUTICAL PARTICULARS

6.1 List of excipients

Sucrose
Xanthan gum
Hydroxypropylcellulose
Trisodium phosphate anhydrous
Silica, colloidal anhydrous
Aspartame (E951)
Cream caramel
Titanium dioxide (E171)

6.2 Incompatibilities

Not applicable.

6.3 Shelf life

Unopened container: Please refer to outer carton.

Reconstituted suspension: The prepared suspension can be kept at up to 30°C for 5 days. Any unused suspension should be discarded after 5 days.

6.4 Special precautions for storage

Unopened container: Store below 30°C.

Reconstituted suspension: Store below 30°C.

6.5 Nature and contents of container

HDPE bottles with a PP/ PE-childproof closure with retaining ring. PE/PP-dosage syringe (10 mL), graduated in 0.25 mL divisions.

Content of the bottle after reconstitution: 15 mL suspension contains 600 mg Azithromycin (as azithromycin monohydrate)

7. PRODUCT REGISTRATION HOLDER

Sandoz Products Malaysia Sdn. Bhd.

3A-2 & 3A-3, Level 3A, Menara KEN TTDI,

No. 37, Jalan Burhanuddin Helmi, Taman Tun Dr Ismail,

60000 Kuala Lumpur, Malaysia

8. DATE OF REVISION OF THE TEXT

Aug 2026